Skip to main content

Table 1 Patient demographic and baseline characteristics

From: Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis

  Comparator (N = 2288)a BIL (N = 3584)a
Type 1 diabetes, n (%) 610 (26.7) 959 (26.8)
Age, years 54.2 ± 13.3 54.0 ± 13.3
Male,  % 58.0 54.7*
Race, n (%)
 American Indian/Alaska native 23 (1.0) 37 (1.0)
 Asian 102 (4.5) 182 (5.1)
 Black/African American 120 (5.2) 182 (5.1)
 Multiple 21 (0.9) 29 (0.8)
 Native Hawaiian/Pacific Islander 4 (0.2) 7 (0.2)
 White 2018 (88.2) 3143 (87.8)
Hispanic or Latino, n (%) 332 (14.5) 580 (16.2)
Region, n (%)
 North America 1019 (44.5) 1611 (45.0)
 European Union 834 (36.5) 1282 (35.8)
 Japan 42 (1.8) 70 (2.0)
 Other 393 (17.2) 621 (17.3)
BMI, kg/m2 30.7 ± 5.7 30.6 ± 5.7
Body weight, kg 88.6 ± 19.5 87.7 ± 19.1
Duration of diabetes, years 14.2 ± 9.4 13.8 ± 9.1
HbA1c,  % 8.2 ± 1.1 8.2 ± 1.1
Hypertension, n (%) 1588 (69.4) 2458 (68.6)
Triglycerides, mg/dL 135 ± 86 139 ± 93
Total cholesterol, mg/dL 176 ± 38 177 ± 39
LDL-C, mg/dL 97 ± 33 98 ± 33
HDL-C, mg/dL 52 ± 16 52 ± 16
History of myocardial infarction, n (%) 93 (4.2) 149 (4.4)
History of coronary revascularization, n (%) 83 (3.8) 121 (3.6)
History of coronary artery bypass graft, n (%) 56 (2.6) 92 (2.7)
Lipid lowering medication, n (%) 1274 (55.7) 1965 (54.8)
 Statin 1165 (50.9) 1787 (49.9)
 Non-statin 316 (13.8) 499 (13.9)
Smoking status, n (%)
 Never used 1279 (58.3) 2013 (59.4)
 Current used 340 (15.5) 507 (15.0)
 Ever used 575 (26.2) 867 (25.6)
  1. Mean ± SD unless otherwise specified. p value >0.05 unless specified
  2. * p = 0.031
  3. aIncludes all randomized patients